Mouse Rat Hybridoma Platform

Hybridoma technology is a method used for producing a large number of identical antibodies, namely monoclonal antibodies (mAbs). MAbs secreted by monoclonal cells with homologous binding specificity to antigenic determinants have been widely applied in diagnostics and therapeutics.

In Creative Biolabs, numerous novel tools have been designed by experts to produce hybridomas and MAbs. Particularly, we have launched a suit of mouse/rat hybridoma platforms, which is a simple, high-efficient and cost-effective strategy suitable for the production of murine mAbs.

Conventional Hybridoma Workflow

Fig.1 Illustration showing the production route of hybridoma technology. (Saeed, 2017)

Hybridoma technology is characterized by an effective fusion of innate functions of both immune and cancer cells, allowing the generation of hybridoma cells, which continuously produces mAbs specific to a desired antigen.

1. I. Immunization;
2. II. Cell isolation and culture;
3. III. Somatic cell fusion;
4. IV. Separation and screening;
5. V. Multiplication.

Advanced Hybridoma™ Platform Technology at Creative Biolabs

Creative Biolabs is an outstanding global service provider across a wide range of biotech fields and our hybridoma team is equipped with technical expertise, high-end facilities, and top-ranking conditions. We have developed a versatile Hybridoma™ Platform, a high-throughput hybridoma generation and screening technology based on novel ClonePix systems, which can provide one-stop, customized mouse/rat hybridoma services for many applications, such as drug development.

Fig.2 Next generation of hybridoma technology based on multitargeting. (Tomita, 2011)

• ▶ Improved mouse/rat hybridoma based on pearl-chain formation
• ▶ Improved mouse/rat hybridoma based on laser radiation
• ▶ Next generation of mouse/rat hybridoma based on B-cell targeting
  1. Selection of sensitized B cells with antigen-biotin
  2. Selection of sensitized B cells with antigen-avidin (or antigen-streptavidin) conjugates
• ▶ Next generation of mouse/rat hybridoma based on multitargeting
• ▶ Next generation of mouse/rat hybridoma based on stereospecific targeting

The proprietary mouse/rat immunization approaches are helpful for the rapid production of mAbs of interest. Through our platforms, clients can find antibodies targeting a wide spectrum of therapeutic targets, including small molecule compounds, soluble proteins, all types of membrane proteins (e.g. epitopes and GPCRs), with minimal affinity and full biological activities.

Key-Benefits

• ✔ High level antibody titer (up to 2,000,000)
• ✔ Shorter immunizing time and high fusion efficiency
• ✔ A time-saving assay cycle (~70 days)
• ✔ High-throughput screening platform available
• ✔ High success rate of harvesting antibodies by ClonePix system
• ✔ Rich experience and better services

Service Guidance

Customers only need to specify their needs and prepare an immunogen, and our engineers will make plans and perform all the following steps to achieve the formation of a hybridoma.

If there is any query regarding our services or quotes, please contact us for more information.

References

1. Saeed, A.F.; et al. Antibody engineering for pursuing a healthier future. Front Microbiol. 2017, 8: 495.
2. Tomita, M.; Tsumoto, K. Hybridoma technologies for antibody production. Immunotherapy. 2011, 3(3): 371-380.

Send